NextCure, Inc.
NXTC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,136 | $24,091 | $7,896 | $8,902 |
| G&A Expenses | $2,809 | $3,201 | $3,726 | $3,553 |
| SG&A Expenses | $2,809 | $3,201 | $3,726 | $3,553 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,945 | $27,292 | $11,622 | $12,455 |
| Operating Income | -$8,945 | -$27,292 | -$11,622 | -$12,455 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $321 | $484 | $646 | $852 |
| Pre-Tax Income | -$8,624 | -$26,808 | -$10,976 | -$11,603 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,624 | -$26,808 | -$10,976 | -$11,603 |
| % Margin | – | – | – | – |
| EPS | -3.22 | -11.29 | -4.703 | -4.972 |
| % Growth | 71.5% | -140.1% | 5.4% | – |
| EPS Diluted | -3.22 | -11.29 | -4.703 | -4.972 |
| Weighted Avg Shares Out | 2,676 | 2,375 | 2,334 | 2,334 |
| Weighted Avg Shares Out Dil | 2,676 | 2,375 | 2,334 | 2,334 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $533 | $633 | $654 | $674 |
| EBITDA | -$8,091 | -$26,659 | -$10,968 | -$11,781 |
| % Margin | – | – | – | – |